Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pharmather Holdings Ltd PHRRF


Primary Symbol: C.PHRM

psychedelics
PharmaTher Holdings Ltd. is a Canada-based specialty pharmaceutical company. The Company develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting delivery methods to enhance patient outcomes. Its lead product is KETARX (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The... see more

Recent & Breaking News (CSE:PHRM)

PharmaTher Collaborates with MediSynergics to Develop Patented Ketamine Formulation for Pain Disorders and to Discover Novel Psychedelic Formulations

GlobeNewswire May 27, 2021

PharmaTher (CSE:PHRM) files application with the FDA to treat ALS with Ketamine

John Ballem  May 25, 2021

PharmaTher Files to FDA to Treat Lou Gehrig’s Disease with Ketamine

Stockhouse Editorial May 25, 2021

PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig's Disease

GlobeNewswire May 25, 2021

Top 5 Stories of the Week HEXO Corp. (TSX:HEXO), PyroGenesis (TSX:PYR), PharmaTher (CSE:PHRM), Vanadium One (TSXV:VONE), Green River Gold Corp. (CCR)

Jocelyn Aspa May 21, 2021

Accomplished Clinical Researcher Matthew Macaluso Joins as Scientific and Clinical Advisor for PharmaTher's Ketamine Programs

GlobeNewswire May 20, 2021

PharmaTher (CSE:PHRM) announces FDA Approval of Ketamine IND

John Ballem  May 17, 2021

Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film Strip

GlobeNewswire May 17, 2021

The World May be Closer to Better Treatments for Parkinson's Disease

Press Releases May 17, 2021

PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson's Disease

GlobeNewswire May 17, 2021

Psychedelics Could Help Treat the 463 Million People Coping with Diabetes

Press Releases April 27, 2021

PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics with panaceAI(TM)

GlobeNewswire April 27, 2021

Help May be On the Way for Patients with Parkinson's Disease

Press Releases April 20, 2021

PharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical Trial Evaluating Ketamine in the Treatment of Parkinson's Disease

GlobeNewswire April 20, 2021

PharmaTher Provides Update on Psychedelic Product Programs

Canadian Press, with file by Stockhouse April 15, 2021

Newscope Announces Name Change to PharmaTher Holdings Ltd.

GlobeNewswire April 13, 2021

Newscope Announces Name Change

GlobeNewswire April 8, 2021

Newscope Capital Provides Dial-In Information for Special Meeting

GlobeNewswire April 1, 2021

PharmaTher Advancing Research for Novel Microneedle Delivery of Ketamine

PR Newswire March 24, 2021

Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application

GlobeNewswire March 19, 2021